Certifect

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

fipronil, amitraz, (S)-methoprene

Available from:

Merial

ATC code:

QP53AX65

INN (International Name):

fipronil / amitraz / (S)-methoprene

Therapeutic group:

Hundar

Therapeutic area:

Ectoparasiticides fyrir baugi nota, meðtalin. skordýraeitur

Therapeutic indications:

Meðferð og koma í veg fyrir sníkjudýra í hunda af ticks (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum og Amblyomma u) og flær (Ctenocephalides sus og Ctenocephalides canis). Meðferð á sýkingum með því að tyggja lús (Trichodectes canis). Forvarnir gegn mengun á umhverfisflóa með því að hindra þróun allra flóru óþroskaðra stiga. Varan er hægt að nota eins og hluti af meðferð áætlun til að stjórna fló-ofnæmi exem. Brotthvarf flóa og flísar innan sólarhrings. Ein meðhöndlun kemur í veg fyrir frekari smit í fimm vikur eftir ticks og í allt að fimm vikur með flórum. Meðferð óbeint dregur úr hættu sendingu merkið-hafa sjúkdóma (hundur babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis og sjúkdómur) frá sýkt ticks fyrir fjórum vikum.

Product summary:

Revision: 5

Authorization status:

Aftakað

Authorization date:

2011-05-06

Patient Information leaflet

                                Lyfið er ekki lengur með markaðsleyfi
B. FYLGISEÐILL
19
Lyfið er ekki lengur með markaðsleyfi
FYLGISEÐILL FYRIR
(Askja með 3 pípettum)
CERTIFECT 67 MG/ 60,3 MG/ 80 MG BLETTUNARLAUSN FYRIR HUNDA 2-10 KG
CERTIFECT 134 MG/ 120,6 MG/ 160 MG BLETTUNARLAUSN FYRIR HUNDA 10-20 KG
CERTIFECT 268 MG/ 241,2 MG/ 320 MG BLETTUNARLAUSN FYRIR HUNDA 20-40 KG
CERTIFECT 402 MG/ 361,8 MG/ 480 MG BLETTUNARLAUSN FYRIR HUNDA 40-60 KG
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi
MERIAL
29, avenue Tony Garnier
FR-69007 Lyon
Frakkland
Framleiðandi sem ber ábyrgð á lokasamþykkt:
MERIAL
4, Chemin du Calquet
FR-31000 Toulouse Cedex
Frakkland
2.
HEITI DÝRALYFS
CERTIFECT 67 mg/ 60,3 mg/ 80 mg blettunarlausn fyrir hunda 2
-
10 kg
CERTIFECT 134 mg/ 120,6 mg/ 160 mg blettunarlausn fyrir hunda 10
-
20 kg
CERTIFECT 268 mg/ 241,2 mg/ 320 mg blettunarlausn fyrir hunda 20
-
40 kg
CERTIFECT 402 mg/ 361,8 mg/ 480 mg blettunarlausn fyrir hunda 40
-
60 kg
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Blettunarlausn (spot-on).
Tær, gulbrún til gulleit lausn.
Úr hverjum stakskammti (tvíhólfa pípettu) fæst:
CERTIFECT blettunarlausn
Rúmmál stakskammta
pípettu (ml)
Fipronil
(mg)
(S)-methoprene
(mg)
Amitraz
(mg)
hundar 2-10 kg
1,07
67,0
60,3
80,0
hundar 10-20 kg
2,14
134,0
120,6
160,0
hundar 20-40 kg
4,28
268,0
241,2
320,0
hundar 40-60 kg
6,42
402,0
361,8
480,0
Hjálparefni sem eru nauðsynleg fyrir rétta lyfjagjöf:
bútýlhýdroxýanísól (0,02 %) og
bútýlhýdroxýtólúen (0,01 %).
20
Lyfið er ekki lengur með markaðsleyfi
4.
ÁBENDING(AR)
Til að meðhöndla og fyrirbyggja blóðmítlasmit (
_Ixodes ricinus, Dermacentor reticulatus, _
_Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis,
Haemaphysalis elliptica, _
_Haemaphysalis longicornis, Amblyomma americanum _
og
_Amblyomma maculatum) _
og flóasmit
_(Ctenocephalides felis _
og
_Ctenocephalides canis)_
hjá hundum.
Meðhöndlun á feldlús (
_Trichodectes canis_
).
Til 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Lyfið er ekki lengur með markaðsleyfi
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
1
Lyfið er ekki lengur með markaðsleyfi
1.
HEITI DÝRALYFS
CERTIFECT 67 mg/ 60,3 mg/ 80 mg blettunarlausn fyrir hunda 2-10 kg
CERTIFECT 134 mg/ 120,6 mg/ 160 mg blettunarlausn fyrir hunda 10-20 kg
CERTIFECT 268 mg/ 241,2 mg/ 320 mg blettunarlausn fyrir hunda 20-40 kg
CERTIFECT 402 mg/ 361,8 mg/ 480 mg blettunarlausn fyrir hunda 40-60 kg
2.
INNIHALDSLÝSING
Virk innihaldsefni:
Úr hverjum stakskammti fæst:
CERTIFECT blettunarlausn
Rúmmál stak-
skammta pípettu (ml)
Fipronil
(mg)
(S)-methoprene
(mg)
Amitraz
(mg)
hundar 2-10 kg
1,07
67
60,3
80
hundar 10-20 kg
2,14
134
120,6
160
hundar 20-40 kg
4,28
268
241,2
320
hundar 40-60 kg
6,42
402
361,8
480
Hjálparefni:
Bútýlhýdroxýanísól (0,02 %)
Bútýlhýdroxýtólúen (0,01 %)
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Blettunarlausn (spot-on).
Tær, gulbrún til gulleit lausn.
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUNDIR
Hundar.
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Til að meðhöndla og fyrirbyggja blóðmítlasmit (
_Ixodes ricinus, Dermacentor reticulatus, _
_Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis,
Haemaphysalis elliptica, _
_Haemaphysalis longicornis, Amblyomma americanum _
og
_Amblyomma maculatum) _
og flóasmit
_(Ctenocephalides felis _
og
_Ctenocephalides canis)_
hjá hundum
_._
Meðhöndlun á feldlús (
_Trichodectes canis_
).
Til að fyrirbyggja flóasmit í umhverfinu með því að hindra
þroska flóa á öllum þroskastigum þeirra.
Lyfið má nota sem hluta af meðferðaráætlun til að hafa stjórn
á húðbólgu vegna flóaofnæmis. Til
útrýmingar á flóm og blóðmítlum á innan við sólarhring.
Stök meðferð kemur í veg fyrir frekari
blóðmítlasmit í 5 vikur og frekara flóasmit í allt að 5 vikur.
Meðferðin dregur, í 4 vikur, óbeint úr hættu á smiti sjúkdóma
sem berast með sýktum blóðmítlum
(canine babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis
og borreliosis)
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-07-2018
Public Assessment Report Public Assessment Report Bulgarian 27-07-2018
Patient Information leaflet Patient Information leaflet Spanish 27-07-2018
Public Assessment Report Public Assessment Report Spanish 27-07-2018
Patient Information leaflet Patient Information leaflet Czech 27-07-2018
Public Assessment Report Public Assessment Report Czech 27-07-2018
Patient Information leaflet Patient Information leaflet Danish 27-07-2018
Public Assessment Report Public Assessment Report Danish 27-07-2018
Patient Information leaflet Patient Information leaflet German 27-07-2018
Public Assessment Report Public Assessment Report German 27-07-2018
Patient Information leaflet Patient Information leaflet Estonian 27-07-2018
Public Assessment Report Public Assessment Report Estonian 27-07-2018
Patient Information leaflet Patient Information leaflet Greek 27-07-2018
Public Assessment Report Public Assessment Report Greek 27-07-2018
Patient Information leaflet Patient Information leaflet English 27-07-2018
Public Assessment Report Public Assessment Report English 27-07-2018
Patient Information leaflet Patient Information leaflet French 27-07-2018
Public Assessment Report Public Assessment Report French 27-07-2018
Patient Information leaflet Patient Information leaflet Italian 27-07-2018
Public Assessment Report Public Assessment Report Italian 27-07-2018
Patient Information leaflet Patient Information leaflet Latvian 27-07-2018
Public Assessment Report Public Assessment Report Latvian 27-07-2018
Patient Information leaflet Patient Information leaflet Lithuanian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-07-2018
Public Assessment Report Public Assessment Report Lithuanian 27-07-2018
Patient Information leaflet Patient Information leaflet Hungarian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 27-07-2018
Public Assessment Report Public Assessment Report Hungarian 27-07-2018
Patient Information leaflet Patient Information leaflet Maltese 27-07-2018
Public Assessment Report Public Assessment Report Maltese 27-07-2018
Patient Information leaflet Patient Information leaflet Dutch 27-07-2018
Public Assessment Report Public Assessment Report Dutch 27-07-2018
Patient Information leaflet Patient Information leaflet Polish 27-07-2018
Public Assessment Report Public Assessment Report Polish 27-07-2018
Patient Information leaflet Patient Information leaflet Portuguese 27-07-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 27-07-2018
Public Assessment Report Public Assessment Report Portuguese 27-07-2018
Patient Information leaflet Patient Information leaflet Romanian 27-07-2018
Public Assessment Report Public Assessment Report Romanian 27-07-2018
Patient Information leaflet Patient Information leaflet Slovak 27-07-2018
Public Assessment Report Public Assessment Report Slovak 27-07-2018
Patient Information leaflet Patient Information leaflet Slovenian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 27-07-2018
Public Assessment Report Public Assessment Report Slovenian 27-07-2018
Patient Information leaflet Patient Information leaflet Finnish 27-07-2018
Public Assessment Report Public Assessment Report Finnish 27-07-2018
Patient Information leaflet Patient Information leaflet Swedish 27-07-2018
Public Assessment Report Public Assessment Report Swedish 27-07-2018
Patient Information leaflet Patient Information leaflet Norwegian 27-07-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 27-07-2018
Patient Information leaflet Patient Information leaflet Croatian 27-07-2018
Public Assessment Report Public Assessment Report Croatian 27-07-2018

View documents history